Probing the mechanistic basis for T cell fate decisions (R01)

探讨T细胞命运决定的机制基础(R01)

基本信息

  • 批准号:
    8702920
  • 负责人:
  • 金额:
    $ 37.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-10 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The TCR-CD3 complex, CD4, and CD28 are vital checkpoint molecules that allow T cells to survey for antigens and activation induced molecules on the surfaces of antigen presenting cells (APCs). They then transfer this antigen- and APC-specific information to the T cell's intracellular signaling apparatus. Ultimately, this informatio directs the T cell fate decisions that drive development, activation, differentiation, and the execution of effector functions. The fundamental importance of these molecules to immune surveillance and human health has resulted in several studies regarding their structure and function over the past 25+ years. As a result, much is now known about their individual structures, their interactions with their respective ligands in isolation, and the signaling cascads that result from these interactions. But, we have yet to determine how they fit and work together as components of the molecular machinery that drives T cell fate decisions and this has prevented us from understanding how this molecular machinery, as a whole, executes its functions. Further, this lack of knowledge has handicapped our ability to strategically target this molecular machinery with reagents designed to either enhance responses to vaccines, tumor, or pathogens, or to attenuate responses to transplants or auto-antigens. Our goal is to deconstruct, understand, and ultimately manipulate the form and function of this complex macromolecular machine. To this end, we will: 1) determine how antigen-specific information is relayed across the membrane by the TCR to the intracellular signaling domains of the CD3 subunits; 2) determine how these signaling subunits are positioned in close proximity with the enzymes that modify them; and 3) determine how the surfaces that stabilize the architecture of this higher order machinery influence CD4+ T cell fate decisions in vivo. We have developed a novel experimental platform that combines classic biochemical and molecular biology techniques with modern polycistronic retroviral systems, kinase- based dimerization assays, and live cell fluorescent video imaging (including the use of total internal reflection fluorescence microscopy (TIRFM) and Forster Resonance Energy Transfer (FRET)), to take a highly controlled reductionist approach to addressing Aim 1 and 2. In addition, we are building novel mouse model systems to accomplish Aim 3. Specifically we will study the surfaces that we have already identified as mediating TCR- CD3 complex stability and TCR dimerization to determine how these interactions, which are at the core of the higher-order macromolecular machinery that transfers pMHC-specific information from the outside to the inside of a cell, influence T cell fate decisions in vivo. Altogether, these experiments will yield important insights into the molecular mechanisms that underlie CD4+ T cell fate decisions and identify potential targets for the development of translational immune-modulating reagents.
描述(由申请人提供):TCR-CD3复合物、CD4和CD28是重要的检查点分子,允许T细胞在抗原呈递细胞(apc)表面调查抗原和激活诱导分子。然后它们将抗原和apc特异性信息传递给T细胞的细胞内信号装置。最终,这些信息指导T细胞的命运决定,驱动发育、激活、分化和执行效应功能。在过去的25年里,这些分子对免疫监测和人类健康的根本重要性导致了一些关于它们的结构和功能的研究。因此,现在对它们的个体结构、它们与各自配体的相互作用以及由这些相互作用产生的信号级联已经有了很多了解。但是,我们还没有确定它们作为驱动T细胞命运决定的分子机制的组成部分是如何配合和一起工作的,这阻碍了我们理解这个分子机制作为一个整体是如何执行其功能的。此外,这种知识的缺乏阻碍了我们在战略上瞄准这一目标的能力

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S Kuhns其他文献

Michael S Kuhns的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S Kuhns', 18)}}的其他基金

Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
设计第二代 5MCAR 来监测和治疗 I 型糖尿病
  • 批准号:
    10598106
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
  • 批准号:
    10705808
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
采用5MCAR技术治疗外周T细胞淋巴瘤
  • 批准号:
    10351121
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
采用5MCAR技术治疗外周T细胞淋巴瘤
  • 批准号:
    10543167
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
设计第二代 5MCAR 来监测和治疗 I 型糖尿病
  • 批准号:
    10435625
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
  • 批准号:
    10570359
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Inducing Tolerance with 5-Module chimeric Antigen Receptor (5MCAR) T Cells
使用 5 模块嵌合抗原受体 (5MCAR) T 细胞诱导耐受
  • 批准号:
    10247395
  • 财政年份:
    2020
  • 资助金额:
    $ 37.88万
  • 项目类别:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
开发识别低亲和力 T 细胞的细胞工具和技术
  • 批准号:
    10259675
  • 财政年份:
    2020
  • 资助金额:
    $ 37.88万
  • 项目类别:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
开发识别低亲和力 T 细胞的细胞工具和技术
  • 批准号:
    9974912
  • 财政年份:
    2020
  • 资助金额:
    $ 37.88万
  • 项目类别:
Probing the mechanistic basis for T cell fate decisions (R01)
探讨T细胞命运决定的机制基础(R01)
  • 批准号:
    10088367
  • 财政年份:
    2012
  • 资助金额:
    $ 37.88万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 37.88万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 37.88万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 37.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 37.88万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 37.88万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 37.88万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 37.88万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 37.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了